Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001892413-26-000002
Filing Date
2026-01-06
Accepted
2026-01-06 20:25:47
Documents
1
Period of Report
2026-01-02

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 6107
  Complete submission text file 0001892413-26-000002.txt   7567
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Issuer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 343 OYSTER POINT BLVD, SUITE 200 SOUTH SAN FRANCISCO CA 94080
Business Address
Kuriakose Emil (Reporting) CIK: 0001892413 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39926 | Film No.: 26513665